Tridek-One, a Paris, France-based biotech startup specialized in the research and development of CD31 agonists to restore the immune balance, raised €16M in funding.
The round was led by Pureos Bioventures with participation from Bpifrance, InnoBio2 fund, Bioqube Ventures, AdBio partners and Advent Life Sciences.
The company intends to use the funds to identify development candidates against auto-immune diseases, to conduct IND-enabling studies and to further build the organization.
Laurence de Schoulepnikoff is a seasoned pharma and biotech professional with broad experience in transactions and R&D operations. She has worked in VC-funded biotech start-ups and mid-size private companies as well as large corporate organizations. De Schoulepnikoff joined Tridek-One from AMAL Therapeutics, a Swiss biotechnology company focused on therapeutic cancer vaccines, where she spent the last three years as chief business officer and chief operating officer. AMAL was acquired by Boehringer Ingelheim in 2019. She will now be leading Tridek-One’s strategy and development, and strengthening its general organization.
Founded in 2018 by Dr. Giuseppina Caligiuri and Pr. Antonino Nicoletti, researchers at INSERM Unit 1148 (Paris, France), and led by newly appointed CEO Laurence de Schoulepnikoff, Tridek-One is a private biotechnology company that develops first-in-class immune checkpoint agonists to restore the immune balance in patients living with auto-immune diseases. It was formed out of INSERM (Paris, France), and backed by a group of international investors that includes Pureos Bioventures, AdBio partners, Bpifrance, Advent Life Sciences and Bioqube Ventures.
Following the fundraising, Klaus Breiner of Pureos Bioventures, and Benoit Barteau of Bpifrance, are joining the company’s board of directors. Erik van den Berg, CEO of AM-Pharma, joins as independent chairman of the board of directors.
FinSMEs
16/09/2022